Article Versions Notes

Ozgol I, Yigit Gencer E, Yildiz C, Karabulut D, Turhan Çaglar FN, Bicakhan B, Yucel C, Ketenciler S, Ay A, Yigit Z. Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence in the Literature. Journal of Clinical Medicine. 2025; 14(20):7395. https://doi.org/10.3390/jcm14207395

Ozgol, Ilhan, Ece Yigit Gencer, Cennet Yildiz, Dilay Karabulut, Fatma Nihan Turhan Çaglar, Burcu Bicakhan, Cihan Yucel, Serkan Ketenciler, Asime Ay, and Zerrin Yigit. 2025. "Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence in the Literature" Journal of Clinical Medicine 14, no. 20: 7395. https://doi.org/10.3390/jcm14207395

Ozgol, I., Yigit Gencer, E., Yildiz, C., Karabulut, D., Turhan Çaglar, F. N., Bicakhan, B., Yucel, C., Ketenciler, S., Ay, A., & Yigit, Z. (2025). Effects of Empagliflozin and Dapagliflozin on Lipid Profiles and Atherogenic Risk Indices in Patients with Heart Failure and a History of CABG: First Evidence in the Literature. Journal of Clinical Medicine, 14(20), 7395. https://doi.org/10.3390/jcm14207395